AdvanSix (NYSE:ASIX - Get Free Report) SVP Achilles Kintiroglou sold 577 shares of the business's stock in a transaction dated Friday, October 3rd. The stock was sold at an average price of $20.00, for a total value of $11,540.00. Following the completion of the sale, the senior vice president directly owned 30,265 shares of the company's stock, valued at $605,300. This represents a 1.87% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link.
AdvanSix Stock Performance
Shares of ASIX stock traded up $0.28 during trading on Friday, reaching $19.67. The company had a trading volume of 312,512 shares, compared to its average volume of 193,123. The firm's 50 day simple moving average is $20.17 and its two-hundred day simple moving average is $21.87. AdvanSix has a one year low of $17.97 and a one year high of $33.00. The company has a debt-to-equity ratio of 0.29, a current ratio of 1.35 and a quick ratio of 0.66. The company has a market capitalization of $528.02 million, a PE ratio of 6.93 and a beta of 1.64.
AdvanSix Dividend Announcement
The firm also recently announced a quarterly dividend, which was paid on Tuesday, August 26th. Stockholders of record on Tuesday, August 12th were given a dividend of $0.16 per share. This represents a $0.64 annualized dividend and a dividend yield of 3.3%. The ex-dividend date was Tuesday, August 12th. AdvanSix's payout ratio is 22.54%.
Institutional Investors Weigh In On AdvanSix
A number of institutional investors and hedge funds have recently modified their holdings of ASIX. Raymond James Financial Inc. bought a new position in AdvanSix in the second quarter valued at approximately $29,000. Osaic Holdings Inc. raised its position in shares of AdvanSix by 60.2% in the 2nd quarter. Osaic Holdings Inc. now owns 1,285 shares of the company's stock valued at $31,000 after acquiring an additional 483 shares during the period. GAMMA Investing LLC grew its holdings in AdvanSix by 149.5% during the first quarter. GAMMA Investing LLC now owns 1,966 shares of the company's stock valued at $45,000 after purchasing an additional 1,178 shares during the period. Tower Research Capital LLC TRC raised its stake in AdvanSix by 144.1% during the 2nd quarter. Tower Research Capital LLC TRC now owns 2,385 shares of the company's stock worth $57,000 after buying an additional 1,408 shares during the period. Finally, Farther Finance Advisors LLC lifted its holdings in shares of AdvanSix by 1,195.9% during the 2nd quarter. Farther Finance Advisors LLC now owns 3,123 shares of the company's stock valued at $74,000 after purchasing an additional 2,882 shares in the last quarter. 86.39% of the stock is owned by institutional investors.
Analyst Upgrades and Downgrades
ASIX has been the subject of several recent research reports. Weiss Ratings reissued a "hold (c-)" rating on shares of AdvanSix in a research report on Saturday, September 27th. Wall Street Zen cut AdvanSix from a "buy" rating to a "hold" rating in a report on Sunday, August 10th. One investment analyst has rated the stock with a Buy rating and one has issued a Hold rating to the company's stock. Based on data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and a consensus price target of $33.50.
Read Our Latest Stock Analysis on ASIX
AdvanSix Company Profile
(
Get Free Report)
AdvanSix Inc engages in the manufacture and sale of polymer resins in the United States and internationally. It offers Nylon 6, a polymer resin, which is a synthetic material used to produce fibers, filaments, engineered plastics, and films. The company also provides caprolactam to manufacture polymer resins; ammonium sulfate fertilizers to distributors, farm cooperatives, and retailers; and acetone that are used in the production of adhesives, paints, coatings, solvents, herbicides, and engineered plastic resins, as well as other intermediate chemicals, including phenol, monoisopropylamine, dipropylamine, monoallylamine, alpha-methylstyrene, cyclohexanone, methyl ethyl ketoxime, acetaldehyde oxime, 2-pentanone oxime, cyclohexanol, sulfuric acid, ammonia, and carbon dioxide.
Further Reading

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider AdvanSix, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and AdvanSix wasn't on the list.
While AdvanSix currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat's analysts have just released their top five short plays for October 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.